Small Molecules

12 Oct 2017 Merck Provides Update on Anacetrapib Development Program
11 Oct 2017 Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer
11 Oct 2017 Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype
11 Oct 2017 MC2 Therapeutics A/S Announces First Patient Dosed in Pivotal US Phase 3 Trial in Psoriasis Vulgaris
11 Oct 2017 Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne
10 Oct 2017 Abide Therapeutics Announces Dosing of First Subject in Phase 1b Study of ABX-1431 in Patients with Neuromyelitis Optica (NMO)
10 Oct 2017 Allergan Announces that the FDA Accepts New Drug Application for Ulipristal Acetate for Uterine Fibroids
10 Oct 2017 Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer
10 Oct 2017 Data Monitoring Committee Unanimously Recommends Continuation of Combioxin First-in-Human Clinical Trial with CAL02 in Patients with Severe Pneumococcal Pneumonia
10 Oct 2017 Entasis Therapeutics Highlights Positive Phase 1 Data for ETX2514 at IDWeek 2017, Announces Plans to Advance Combination with sulbactam (ETX2514SUL) into Phase 2 Trials
10 Oct 2017 Arsanis Presents Phase 1 and Preclinical Pharmacokinetic Data on Lead Product Candidate, ASN100, at IDWeek™ 2017
10 Oct 2017 Clovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
10 Oct 2017 GNI Group Announces Clearance of Investigational New Drug (IND) by FDA for F351 Clinical Trials in the Treatment of Liver Fibrosis
10 Oct 2017 OncoArendi Therapeutics to Begin the Phase 1 Clinical Evaluation of its Novel Class of Medicines
10 Oct 2017 Amplyx Pharmaceuticals Highlights Phase 1 APX001 Data at IDWeek 2017
09 Oct 2017 EDO announces next milestone for tinostamustine (EDO-S101) as first-in-human solid tumor study begins
09 Oct 2017 Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer
07 Oct 2017 Flexion Therapeutics Announces FDA Approval of Zilretta™ (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis (OA) Knee Pain
06 Oct 2017 Neurocrine Announces FDA Approval of 80 mg INGREZZA® (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD)
06 Oct 2017 SPARC Provides Update on Pivotal Phase III Studies of Baclofen GRS for Treatment of Spasticity in Patients with Multiple Sclerosis
06 Oct 2017 NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms
05 Oct 2017 Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens
04 Oct 2017 Melior Pharmaceuticals Initiates Phase 2b Study with MLR-1023 for Type 2 Diabetes
04 Oct 2017 Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD® Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial in First Half 2018
04 Oct 2017 Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Meniere's Disease

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing